IP Library Granted Patent US 9,895,199
Granted Patent B2
US 9,895,199 · App. 14/301,692 · Granted Feb 20, 2018

Devices and methods for engaging indexed valve and pressurized canister assembly with collar and for linear actuation by plunger assembly into fluid communication with device for regulating drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,199
App. No.
14/301,692
Granted
Feb 20, 2018
Kind
B2
Abstract

A valve assembly comprising a housing and a valve, the valve being disposed within the housing, a first indexed member integral to the housing, the first indexed member adapted to be complementary to a second indexed member, and a radio frequency identification device adapted to communicate with a radio frequency receiver, the valve being configured to align with a canister, seal the canister and open in a single movement. A drug containment device having said valve assembly is also disclosed.

Claims (42)

1. An indexed drug containment device assembly for a drug delivery and regulation device, the indexed drug containment device assembly comprising:

a gas canister containing an active pharmaceutical ingredient and an inactive gas carrier for delivery to a patient in need thereof via the drug delivery and regulation device,

a housing and a spring biased needle valve, at least a portion of the spring biased needle valve being disposed within the housing and regulating fluid flow from the gas canister by actuating along a longitudinal axis of the gas canister, and,

a first indexed member integral to the housing and comprising a first arcuate opening and a second arcuate opening that extend arcuately about, and on at least a portion of opposing sides of, the longitudinal axis of the gas canister, the first and second arcuate openings having at least one of different axial widths or misaligned mid planes, the first indexed member adapted to complementarily engage a second indexed member of the drug delivery and regulation device to provide sufficient engagement for actuation of the spring biased needle valve and so that the indexed drug containment device assembly seats into, and is removable from, the drug delivery and regulation device when aligned via a relative movement that is perpendicular to the longitudinal axis; and

wherein, when complementarily engaged, the indexed drug containment device assembly aligns, seals, opens, and is secured in the drug delivery and regulation device in a single movement.

2. An indexed drug containment device assembly for a drug delivery and regulation device, the indexed drug containment device assembly comprising:

a gas canister containing an active pharmaceutical ingredient and an inactive gas carrier for delivery to a patient in need thereof via the drug delivery and regulation device, the gas canister having a valve regulating fluid flow from the gas canister by actuating along a longitudinal axis of the gas canister;

a housing encasing at least a portion of the valve, the housing having a first indexed member integral to the housing;

the first indexed member comprising a first arcuate opening and a second arcuate opening that extend arcuately about, and on at least a portion of opposing sides of, the longitudinal axis of the gas canister, the first and second arcuate openings having at least one of different axial widths or misaligned mid planes, the first indexed member is adapted to complementarily engage a second indexed member of the drug delivery and regulation device to provide sufficient engagement for actuation of the valve and so that the indexed drug containment device assembly seats into, and is removable from, the drug delivery and regulation device when aligned via a relative movement that is perpendicular to the longitudinal axis; and

wherein, when complementarily engaged, the indexed drug containment device assembly aligns, seals, opens, and is secured in the drug delivery and regulation device in a single movement.

3. An indexed drug containment device assembly for a drug delivery and regulation device, the indexed drug containment device assembly comprising:

a gas canister having a valve regulating flow of an active pharmaceutical ingredient contained in the gas canister, for delivery to a patient in need thereof via the drug delivery and regulation device, by actuating along a longitudinal axis of the gas canister;

a housing encasing at least a portion of the valve, the housing having a first indexed member;

the first indexed member comprising a first arcuate opening and a second arcuate opening that extend arcuately about, and on at least a portion of opposing sides of, the longitudinal axis of the gas canister, the first and second arcuate openings having at least one of different axial widths or misaligned mid-planes, the first indexed member adapted to complementarily engage a second indexed member of the drug delivery and regulation device when aligned; and

wherein, when complementarily engaged, the indexed drug containment device assembly aligns, seals, opens, and is secured in the drug delivery and regulation device in a single movement.

4. The assembly of claim 3 , wherein the first indexed member is adapted to complementarily engage the second indexed member of the drug delivery and regulation device to provide sufficient engagement for actuation of the valve and so that the indexed drug containment device assembly seats into, and is removable from, the drug delivery and regulation device when aligned via a relative movement that is perpendicular to the longitudinal axis.

5. The assembly of claim 3 , wherein the active pharmaceutical ingredient comprises at least one of:

nitric oxide, with a concentration in the range of approximately 50 ppm to 10,000 ppm,

carbon monoxide, with a concentration in the range of approximately 500 ppm to 20,000 ppm, and,

a chalcogenide compound,

wherein the gas canister also contains an inactive carrier gas comprising at least one of N 2 or O 2 .

6. The assembly of claim 3 , wherein the first arcuate opening is directly opposite from the second arcuate opening.

7. The assembly of claim 3 , wherein the gas canister contains nitric oxide with a concentration in the range of approximately 2,400 ppm to approximately 10,000 ppm and an inactive gas carrier comprising N 2 .

8. The assembly of claim 3 , wherein the first and second arcuate openings have different axial widths and misaligned mid-planes.

9. The assembly of claim 3 , wherein the complementary engagement of the first and second indexed members provides sufficient engagement to permit actuation of the valve.

10. The assembly of claim 3 , wherein the indexed drug containment device assembly is removable from the drug delivery and regulation device via a relative movement that is perpendicular to the longitudinal axis.

11. The assembly of claim 3 , further comprising a radio frequency identification device adapted to communicate with a radio frequency receiver.

12. The assembly of claim 3 , wherein the first indexed member is configured to be a support enabling the indexed drug containment device assembly to be suspended vertically in the drug delivery and regulation device.

13. The assembly of claim 3 , wherein first indexed member is configured to be a support permitting actuation of the valve along the longitudinal axis of the gas canister.

14. The assembly of claim 3 , wherein the first indexed member is configured to be a support enabling suspending the indexed drug containment device assembly in the drug delivery and regulation device and permitting actuation of the valve along the longitudinal axis of the gas canister.

15. The assembly of claim 3 , wherein one or more of the first indexed member and the second indexed member have a surface that is configured to be an at least one support enabling the indexed drug containment device assembly to be seated in the drug delivery and regulation device and permitting actuation of the valve along the longitudinal axis of the gas canister.

16. An indexed drug delivery system comprising:

the assembly of claim 3 ; and

the drug delivery and regulation device comprising the second indexed member.

17. An indexed drug containment device assembly for a drug delivery and regulation device, the indexed drug containment device assembly comprising:

a gas canister having a valve regulating flow of an active pharmaceutical ingredient contained in the gas canister, for delivery to a patient in need thereof via the drug delivery and regulation device, by actuating along a longitudinal axis of the gas canister;

a housing encasing at least a portion of the valve and having a first indexing member, the first indexing member being adapted to complementarily engage a second indexed member of the drug delivery and regulation device to (i) ensure the gas canister is at least one of the desired gas canister and containing the desired therapeutic gas drug, (ii) suspend the indexed drug containment device assembly in the drug delivery and regulation device, and (iii) provide sufficient engagement to permit actuation of the valve; and

wherein, when complementarily engaged, the indexed drug containment device assembly aligns, seals, opens, and is secured in the drug delivery and regulation device in a single movement.

18. The assembly of claim 17 , wherein the first and second indexed members are adapted to complementarily engage when aligned via a relative movement that is perpendicular to the longitudinal axis of the gas canister.

19. The assembly of claim 17 , wherein the first indexing member comprises a first arcuate opening and a second arcuate opening arcuately about, and on at least a portion of opposing sides of, the longitudinal axis of the portable gas canister, the first and second arcuate openings having at least one of different axial widths or misaligned mid planes.

20. The assembly of claim 19 , wherein the first and second arcuate openings have different axial widths and misaligned mid-planes.

21. The assembly of claim 17 , wherein the active pharmaceutical ingredient comprises nitric oxide.

Assignments (18)
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0454 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0035 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049822/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2016
From: MALLINCKRODT IP
To: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
Reel/Frame 038009/0016 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2016
From: MALLINCKRODT PHARMA IP TRADING DAC
To: MALLINCKRODT IP
Reel/Frame 038009/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2016
From: MALLINCKRODT CRITICAL CARE FINANCE INC.
To: MALLINCKRODT PHARMA IP TRADING DAC
Reel/Frame 038038/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2016
From: INO THERAPEUTICS LLC
To: THERAKOS, INC.
Reel/Frame 038008/0956 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2016
From: THERAKOS, INC.
To: MALLINCKRODT CRITICAL CARE FINANCE INC.
Reel/Frame 038008/0824 →